DD,
XOMA has been a once or twice yearly recommendation of
Jim McCamant, a medical stock newsletter writer out of
California, for at least the last year. Sometimes when
he picks it as a possible candidate for great things
(in a small column or such in Worth or Smart Money?)
it'll pop a bit. I held it for awhile last year, too. Can't
remember if I won or lost on it.
The part of the Neuprex's (their lead drug) story that
particularly interests me is it's possible use to combat
serious infections from abdominal wounds. Car accidents,
GSW's, stabbings, etc. These can real easily get fatal,
and their a regular part of life these days. Assuming it's
a product with a shelf life, ER's could be up against a
situation of needing to keep a supply on hand, whether
they're using it or not.
Has to get approved first, 'tho, and I'm not crazy about
the above mentioned cash-burn rate.
Lee |
